Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
ANNÉE
2019
AUTEURS
Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lievre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges J,-P, Faroux R, Gaba L, Manfredi S, Tougeron D
CONGRÈS/REVUE
ESMO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES